Oxidative stress assessment in sickle cell anemia patients treated with hydroxyurea

Ann Hematol. 2020 May;99(5):937-945. doi: 10.1007/s00277-020-03987-7. Epub 2020 Mar 12.

Abstract

Hydroxyurea (HU) is used as a therapy in sickle cell anemia (SCA). Many studies have established that HU improves patient quality of life by reducing symptoms. However, the effect of HU on erythrocytes is not well-described. We evaluated several parameters related to oxidative stress and total lipid content of erythrocytes in patients with SCA. The patient cohort consisted of 7 SCA patients treated with HU, 17 untreated SCA patients, and 15 healthy subjects. Erythrocytes from patients with SCA displayed increased oxidative stress relative to the control group, including higher thiobarbituric acid reactive substances (TBARS), Fe3+ content, and osmotic fragility, and decreased total cholesterol. We observed that treatment of SCA patients with HU increased Fe3+ content and activity of glutathione peroxidase, and decreased glutathione reductase activity, glutathione levels, total cholesterol, and phospholipid content comaperaded to patients untreated with HU. Thus, HU alters biochemical characteristics of erythrocytes; future studies will determine whether they are beneficial or not.

Keywords: Erythrocyte membrane; Hydroxyurea; Oxidative stress; Sickle cell anemia.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Anemia, Sickle Cell* / blood
  • Anemia, Sickle Cell* / drug therapy
  • Cholesterol / blood
  • Erythrocytes, Abnormal / metabolism*
  • Female
  • Humans
  • Hydroxyurea / administration & dosage*
  • Male
  • Osmotic Fragility / drug effects
  • Oxidative Stress / drug effects*
  • Phospholipids / blood
  • Thiobarbituric Acid Reactive Substances / metabolism

Substances

  • Phospholipids
  • Thiobarbituric Acid Reactive Substances
  • Cholesterol
  • Hydroxyurea